-
公开(公告)号:US20200247869A1
公开(公告)日:2020-08-06
申请号:US16838395
申请日:2020-04-02
申请人: The United States of America,as represented by the Secretary,Department of Health and Human Services
发明人: Eric Tran , Yong-Chen Lu , Anna Pasetto , Paul F. Robbins , Steven A. Rosenberg , Zhili Zheng
IPC分类号: C07K14/725 , C12N15/85 , A61P35/00 , G01N33/574 , C07K14/82
摘要: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
-
公开(公告)号:US20230089465A1
公开(公告)日:2023-03-23
申请号:US17936006
申请日:2022-09-28
申请人: The United States of America,as represented by the Secretary,Department of Health and Human Services
发明人: Paul F. Robbins , Steven A. Rosenberg , Xin Yao
IPC分类号: C07K14/725 , A61K38/17 , C07K14/73 , A61K39/00 , C07K16/00 , C07K16/28 , G01N33/574
摘要: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
-
公开(公告)号:US11208456B2
公开(公告)日:2021-12-28
申请号:US16838395
申请日:2020-04-02
发明人: Eric Tran , Yong-Chen Lu , Anna Pasetto , Paul F. Robbins , Steven A. Rosenberg , Zhili Zheng
IPC分类号: C07K14/82 , A61P35/00 , A61K38/00 , C12N15/85 , C07K14/725 , G01N33/574
摘要: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
-
4.
公开(公告)号:US20200017831A1
公开(公告)日:2020-01-16
申请号:US16334872
申请日:2017-09-18
申请人: The United States of America,as represented by the Secretary,Department of Health and Human Services
IPC分类号: C12N5/0784 , A61K35/15
摘要: Disclosed are methods of preparing an isolated population of dendritic cells, isolated populations of dendritic cells prepared by the methods, and pharmaceutical compositions comprising the isolated population of dendritic cells. Also disclosed are methods of treating or preventing cancer using the isolated population of dendritic cells or pharmaceutical compositions.
-
公开(公告)号:US20190177395A1
公开(公告)日:2019-06-13
申请号:US16321899
申请日:2017-07-31
申请人: The United States of America,as represented by the Secretary,Department of Health and Human Services
发明人: Eric Tran , Yong-Chen Lu , Anna Pasetto , Paul F. Robbins , Steven A. Rosenberg , Zhili Zheng
IPC分类号: C07K14/725 , C12N15/85 , C07K14/82 , A61P35/00 , G01N33/574
摘要: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
-
公开(公告)号:US11306132B2
公开(公告)日:2022-04-19
申请号:US16135231
申请日:2018-09-19
IPC分类号: C07K14/725 , A61K35/17 , G01N33/574 , A61K38/17 , A61P35/00 , C12N15/62 , C07K14/82
摘要: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
-
公开(公告)号:US20220089677A1
公开(公告)日:2022-03-24
申请号:US17541619
申请日:2021-12-03
申请人: The United States of America,as represented by the Secretary,Department of Health and Human Services
发明人: Eric Tran , Yong-Chen Lu , Anna Pasetto , Paul F. Robbins , Steven A. Rosenberg , Zhili Zheng
IPC分类号: C07K14/725 , C07K14/82 , G01N33/574 , A61P35/00 , C12N15/85
摘要: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
-
公开(公告)号:US09879065B2
公开(公告)日:2018-01-30
申请号:US14427671
申请日:2013-09-13
发明人: Paul F. Robbins , Steven A. Rosenberg , Xin Yao
IPC分类号: A61K39/395 , C07K14/725 , A61K38/17 , C07K14/73 , A61K39/00 , C07K16/00 , C07K16/28 , G01N33/574
CPC分类号: C07K14/7051 , A61K38/1774 , A61K39/0005 , A61K2039/585 , C07K14/70514 , C07K16/00 , C07K16/2809 , C07K2319/00 , G01N33/57492 , G01N2333/47 , G01N2333/7051
摘要: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
-
公开(公告)号:US20220204584A1
公开(公告)日:2022-06-30
申请号:US17692787
申请日:2022-03-11
申请人: The United States of America,as represented by the Secretary,Department of Health and Human Services
发明人: Gal Cafri , Paul F. Robbins , Steven A. Rosenberg
IPC分类号: C07K14/725 , G01N33/574 , A61K38/17 , A61K35/17 , A61P35/00 , C12N15/62 , C07K14/82
摘要: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
-
10.
公开(公告)号:US20210220457A1
公开(公告)日:2021-07-22
申请号:US17195072
申请日:2021-03-08
申请人: The United States of America,as represented by the Secretary,Department of Health and Human Services
发明人: Eric Tran , Yong-Chen Lu , Paul F. Robbins , Steven A. Rosenberg
IPC分类号: A61K39/00 , C12N5/0783 , C12Q1/6886
摘要: Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.
-
-
-
-
-
-
-
-
-